Tuesday, January 11, 2011
Cephalon, Inc., of Frazer, Pa., announced positive interim results from an ongoing multicenter Phase II trial of its "off-the-shelf" adult stem cell product Revascor for patients with congestive heart failure.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.